Snowflake Inc. SNOW
Regular-session close
After hours · Nov 16, 7:57 PM ET
- YTD
- +27.89%
- 1 year
- +9.15%
Discussion (414)
$SNOW I’ll wait to get in after ER or below 200.
For beginners in trading and investing, it's crucial to grasp that success in these fields goes beyond just technical analysis. Consistently investing over an extended period typically yields better results than attempting to time the market through short-term buying and selling based on fluctuations. Learning plays a vital role in achieving success in trading and investing. Staying updated on current trends and strategies can assist businesses in staying ahead of the curve and making well-informed decisions. I'm pleased that the insights and strategies have proven beneficial to me. Presently, I am generating $17,500 every ten days with my initial investment of $1,700. Feel free to reach out to ?Salome_crypto_trader via direct message on Instagram to kickstart your journey?.https://www.instagram.com/salome_crypto_trader?igsh=MW5zOGdtb3lieGU3MQ==

?
Trade with the #1 broker ERIC_TRED1-visit his account on INSTAGRAM and make a plan. Trading with him has saved me a lot of losses and I have earned so much interest using his brokerage, getting signals, recovering lost funds and multiplying your finances. A great way to keep your earnings updated. My $600 on his brokerage brought in $5,800 in a three-day trading period.
Why is down when the market after hours is going up
$PTC Therapeutics(PTCT.US)$ ?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.
